-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purpose: In active early rheumatoid arthritis (RA) , glucocorticoids are often used for bridging due to the delayed effects of methotrexa.
Purpose: In active early rheumatoid arthritis (RA) , glucocorticoids are often used for bridging due to the delayed effects of methotrexa.
Methods: Adult RA patients with moderate / high disease activity from one rheumatology hospital and 23 rheumatology treatment centers were randomized (1:1:1) to 60 mg (high dose, HDP ) and 10 mg daily Prednisolone (low dose, LDP , tapering to 0 mg over 12 weeks ) or placeb.
Methods: Adult RA patients with moderate / high disease activity from one rheumatology hospital and 23 rheumatology treatment centers were randomized (1:1:1) to 60 mg (high dose, HDP ) and 10 mg daily Prednisolone (low dose, LDP , tapering to 0 mg over 12 weeks ) or placeb.
RESULTS: Of 395 randomized patients ( n=132 high-dose group, n=131 low-dose group, n=132 placebo), 375 ( 95% ) remained in the modified intention-to-treat analys.
Conclusions: The results of this study showed that high-dose short-term glucocorticoid bridging (bridging) therapy did not have any benefit on the progression of radiographic damage in patients with rheumatoid arthritis within one ye.
Krause,.
, Mai,.
, Klaassen-Mielke,.
, et .
(2022), The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis : a double-blind, randomized, placebo-controlled tri.
Arthritis Rheumat.
Accepted Author Manuscri.
https://d.
org/11002/a.
42245 Leave a comment here